- Home
- SWIM vs QURE Comparison
SWIM vs QURE Comparison
Compare SWIM & QURE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWIM
- QURE
- Stock Information
- Founded
- SWIM 1956
- QURE 1998
- Country
- SWIM United States
- QURE Netherlands
- Employees
- SWIM 1800
- QURE N/A
- Industry
- SWIM Plastic Products
- QURE Biotechnology: Pharmaceutical Preparations
- Sector
- SWIM Industrials
- QURE Health Care
- Exchange
- SWIM Nasdaq
- QURE Nasdaq
- Market Cap
- SWIM 839.1M
- QURE 4.3B
- IPO Year
- SWIM 2021
- QURE 2007
- Fundamental
- Price
- SWIM $6.95
- QURE $26.06
- Analyst Decision
- SWIM Hold
- QURE Strong Buy
- Analyst Count
- SWIM 4
- QURE 13
- Target Price
- SWIM $7.20
- QURE $64.67
- AVG Volume (30 Days)
- SWIM 513.0K
- QURE 4.1M
- Earning Date
- SWIM 11-04-2025
- QURE 10-29-2025
- Dividend Yield
- SWIM N/A
- QURE N/A
- EPS Growth
- SWIM N/A
- QURE N/A
- EPS
- SWIM N/A
- QURE N/A
- Revenue
- SWIM $533,235,000.00
- QURE $14,337,000.00
- Revenue This Year
- SWIM $9.17
- QURE N/A
- Revenue Next Year
- SWIM $5.38
- QURE $229.18
- P/E Ratio
- SWIM N/A
- QURE N/A
- Revenue Growth
- SWIM 4.12
- QURE N/A
- 52 Week Low
- SWIM $4.56
- QURE $5.35
- 52 Week High
- SWIM $8.46
- QURE $71.50
- Technical
- Relative Strength Index (RSI)
- SWIM 36.38
- QURE 29.06
- Support Level
- SWIM $7.03
- QURE $22.85
- Resistance Level
- SWIM $7.44
- QURE $71.50
- Average True Range (ATR)
- SWIM 0.29
- QURE 4.30
- MACD
- SWIM -0.05
- QURE -5.54
- Stochastic Oscillator
- SWIM 25.72
- QURE 6.60
About SWIM Latham Group Inc.
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.
About QURE uniQure N.V.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.